{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:35:01Z","timestamp":1791920101479,"version":"4.3.4"},"reference-count":147,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010198","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RTI2018-101936-B-I00"],"award-info":[{"award-number":["RTI2018-101936-B-I00"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jhepr.2021.100300","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T01:04:58Z","timestamp":1619744698000},"page":"100300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["Novel vectors and approaches for gene therapy in liver diseases"],"prefix":"10.1016","volume":"3","author":[{"given":"Sheila","family":"Maestro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Zabaleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Aldabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Gonzalez-Aseguinolaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2021.100300_bib1","series-title":"Gene and cell therapy FAQs","year":"2019"},{"key":"10.1016\/j.jhepr.2021.100300_bib2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T\u00a0lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2021.100300_bib3","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1126\/science.270.5235.470","article-title":"Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients","volume":"270","author":"Bordignon","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2021.100300_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jhepr.2021.100300_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJM200301163480314","article-title":"A\u00a0serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency","volume":"348","author":"Hacein-Bey-Abina","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3015","article-title":"Gene therapy clinical trials worldwide to 2017: an update","volume":"20","author":"Ginn","year":"2018","journal-title":"J\u00a0Gene Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib7","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fgene.2019.00868","article-title":"Development and clinical translation of approved gene therapy products for genetic disorders","volume":"10","author":"Shahryari","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.jhepr.2021.100300_bib8","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1038\/s41467-020-19505-2","article-title":"The once and future gene therapy","volume":"11","author":"Bulaklak","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2021.100300_bib9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jhep.2020.08.003","article-title":"Gene therapies targeting the liver","volume":"74","author":"Cozmescu","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100300_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10545-017-0053-3","article-title":"Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects","volume":"40","author":"Baruteau","year":"2017","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.jhepr.2021.100300_bib11","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1089\/hum.2019.140","article-title":"Genetic-based approaches to inherited metabolic liver diseases","volume":"30","author":"Zabaleta","year":"2019","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/diseases4040033","article-title":"Genetic substrate reduction therapy: a promising approach for lysosomal storage disorders","volume":"4","author":"Coutinho","year":"2016","journal-title":"Diseases"},{"key":"10.1016\/j.jhepr.2021.100300_bib13","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1136\/gutjnl-2016-313565","article-title":"CRISPR\/Cas9: at the cutting edge of hepatology","volume":"66","author":"Pankowicz","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100300_bib14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ejmg.2018.04.010","article-title":"Improved molecular platform for the gene therapy of rare diseases by liver protein secretion","volume":"61","author":"Quiviger","year":"2018","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.jhepr.2021.100300_bib15","article-title":"Gene therapy for hemophilia: facts and quandaries in the 21st century","volume":"12","author":"Arruda","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.jhepr.2021.100300_bib16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00109-020-01935-6","article-title":"Lysosomal storage diseases: current therapies and future alternatives","volume":"98","author":"Leal","year":"2020","journal-title":"J\u00a0Mol Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0076-6879(02)46050-8","article-title":"Hydrodynamics-based transfection: simple and efficient method for introducing and expressing transgenes in animals by intravenous injection of DNA","volume":"346","author":"Song","year":"2002","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.jhepr.2021.100300_bib18","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1089\/10430349950017734","article-title":"High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA","volume":"10","author":"Zhang","year":"1999","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3390\/genes9030136","article-title":"Translational advances of hydrofection by hydrodynamic injection","volume":"9","author":"Sandra","year":"2018","journal-title":"Genes"},{"key":"10.1016\/j.jhepr.2021.100300_bib20","doi-asserted-by":"crossref","first-page":"8862","DOI":"10.3748\/wjg.v22.i40.8862","article-title":"Liver-targeted hydrodynamic gene therapy: recent advances in the technique","volume":"22","author":"Yokoo","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2021.100300_bib21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0014-5793(96)00590-X","article-title":"In\u00a0vivo gene electroinjection and expression in rat liver","volume":"389","author":"Heller","year":"1996","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jhepr.2021.100300_bib22","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/pharmaceutics12090793","article-title":"In\u00a0vivo electroporation-mediated, intrahepatic Alpha1 antitrypsin gene transfer reduces pulmonary emphysema in pallid mice","volume":"12","author":"Sutter","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jhepr.2021.100300_bib23","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3390\/pharmaceutics12100964","article-title":"Microbubbles and nanobubbles with ultrasound for systemic gene delivery","volume":"12","author":"Endo-Takahashi","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jhepr.2021.100300_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.omtm.2018.06.008","article-title":"Ultrasound-mediated gene therapy in swine livers using single-element, multi-lensed, high-intensity ultrasound transducers","volume":"10","author":"Noble-Vranish","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jhepr.2021.100300_bib25","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1242\/jcs.00976","article-title":"Chromatin loops are selectively anchored using scaffold\/matrix-attachment regions","volume":"117","author":"Heng","year":"2004","journal-title":"J\u00a0Cell Sci"},{"key":"10.1016\/j.jhepr.2021.100300_bib26","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1007\/s11033-019-04777-9","article-title":"Efficient episomal gene transfer to human hepatic cells using the pFAR4-S\/MAR vector","volume":"46","author":"Giannakopoulos","year":"2019","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.jhepr.2021.100300_bib27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/genetics\/26.2.234","article-title":"The stability of broken ends of chromosomes in zea mays","volume":"26","author":"McClintock","year":"1941","journal-title":"Genetics"},{"key":"10.1016\/j.jhepr.2021.100300_bib28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1266\/ggs.94.231","article-title":"Evolution of transposable elements and evolution of eukaryote genomes mediated by transposable elements","volume":"94","author":"Nishihara","year":"2019","journal-title":"Genes Genet Syst"},{"key":"10.1016\/j.jhepr.2021.100300_bib29","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1038\/mtna.2015.54","article-title":"A\u00a0broad range of dose optima achieve high-level, long-term gene expression\u00a0after hydrodynamic delivery of sleeping beauty transposons using hyperactive SB100x transposase","volume":"5","author":"Podetz-Pedersen","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jhepr.2021.100300_bib30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2174\/156652311797415827","article-title":"Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies","volume":"11","author":"Hackett","year":"2011","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/mt.2009.302","article-title":"piggyBack transposon-mediated long-term gene expression in mice","volume":"18","author":"Nakanishi","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib32","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/mt.2014.131","article-title":"Hyperactive piggyBac transposons for sustained and robust liver-targeted gene therapy","volume":"22","author":"Di Matteo","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib33","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jhep.2017.05.012","article-title":"Therapeutic editing of hepatocyte genome in\u00a0vivo","volume":"67","author":"Ruiz de Galarreta","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100300_bib34","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.ymthe.2018.03.002","article-title":"Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in\u00a0vivo genome editing","volume":"26","author":"Laoharawee","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib35","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ymthe.2018.10.018","article-title":"ZFN-mediated in\u00a0vivo genome editing corrects murine hurler syndrome","volume":"27","author":"Ou","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib36","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhepr.2019.09.002","article-title":"Using CRISPR\/Cas9 to model human liver disease","volume":"1","author":"Alves-Bezerra","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2021.100300_bib37","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","article-title":"CRISPR gene therapy: applications, limitations, and implications for the future","volume":"10","author":"Uddin","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhepr.2021.100300_bib38","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.7150\/ijbs.33481","article-title":"CRISPR\/Cas9-related technologies in liver diseases: from feasibility to future diversity","volume":"16","author":"Xu","year":"2020","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.jhepr.2021.100300_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202003537","article-title":"A\u00a0versatile nonviral delivery system for multiplex gene-editing in the liver","volume":"32","author":"Gong","year":"2020","journal-title":"Adv Mater"},{"key":"10.1016\/j.jhepr.2021.100300_bib40","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1038\/s41467-018-07827-1","article-title":"CRISPR\/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I","volume":"9","author":"Zabaleta","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2021.100300_bib41","doi-asserted-by":"crossref","first-page":"12642","DOI":"10.1038\/ncomms12642","article-title":"Reprogramming metabolic pathways in\u00a0vivo with CRISPR\/Cas9 genome\u00a0editing to treat hereditary tyrosinaemia","volume":"7","author":"Pankowicz","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2021.100300_bib42","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","article-title":"Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics","volume":"6","author":"Huang","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jhepr.2021.100300_bib43","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib44","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib45","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1681\/ASN.2016030338","article-title":"An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria","volume":"28","author":"Liebow","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jhepr.2021.100300_bib46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1056\/NEJMra1705346","article-title":"Treating disease at the RNA level with oligonucleotides","volume":"380","author":"Levin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib47","article-title":"Oligonucleotide-based therapeutics: an emerging strategy for the treatment of chronic liver diseases","author":"Alkhouri","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100300_bib48","doi-asserted-by":"crossref","first-page":"100177","DOI":"10.1016\/j.jhepr.2020.100177","article-title":"Our emerging understanding of the roles of long non-coding RNAs in normal liver function, disease, and malignancy","volume":"3","author":"Mahpour","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2021.100300_bib49","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejpb.2004.11.011","article-title":"Polyethylenimine-based non-viral gene delivery systems","volume":"60","author":"Lungwitz","year":"2005","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.jhepr.2021.100300_bib50","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s13346-020-00790-9","article-title":"PEI fluorination reduces toxicity and promotes liver-targeted siRNA delivery","volume":"11","author":"Xue","year":"2021","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.jhepr.2021.100300_bib51","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.addr.2020.06.026","article-title":"Lipid nanoparticle technology for therapeutic gene regulation in the liver","volume":"159","author":"Witzigmann","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jhepr.2021.100300_bib52","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhepr.2021.100300_bib53","article-title":"Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB\/c.Abcb4-\/- mouse model of PFIC3","volume":"20","author":"Wei","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100300_bib54","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1038\/s41467-020-19156-3","article-title":"Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia","volume":"11","author":"Jiang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2021.100300_bib55","doi-asserted-by":"crossref","first-page":"21150","DOI":"10.1073\/pnas.1906182116","article-title":"Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency","volume":"116","author":"Truong","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.jhepr.2021.100300_bib56","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.ymthe.2019.04.017","article-title":"mRNA therapy improves metabolic and behavioral abnormalities in a murine model of citrin deficiency","volume":"27","author":"Cao","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib57","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","article-title":"Systemic messenger RNA therapy as a treatment for methylmalonic acidemia","volume":"21","author":"An","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhepr.2021.100300_bib58","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-018-0199-z","article-title":"Systemic messenger RNA as an etiological treatment for acute intermittent porphyria","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib59","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ymthe.2017.12.024","article-title":"Targeted mRNA therapy for ornithine transcarbamylase deficiency","volume":"26","author":"Prieve","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib60","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.jhepr.2021.100300_bib61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1474-4422(20)30397-5","article-title":"Patisiran in hereditary transthyretin-mediated amyloidosis","volume":"20","author":"Luigetti","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jhepr.2021.100300_bib62","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib63","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2018-0838","article-title":"An open-label, multicenter, phase I, dose escalation study with phase II expansion cohort to determine the safety, pharmacokinetics, and preliminary antitumor activity of intravenous TKM-080301 in subjects with advanced hepatocellular carcinoma","volume":"24","author":"El Dika","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jhepr.2021.100300_bib64","first-page":"3187","article-title":"New approaches to the treatment of chronic hepatitis B","volume":"9","author":"Alexopoulou","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib65","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ymthe.2019.03.003","article-title":"Non-viral delivery of zinc finger nuclease mRNA enables highly efficient in\u00a0vivo genome editing of multiple therapeutic gene targets","volume":"27","author":"Conway","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib66","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/CMR.00008-08","article-title":"Gene therapy using adeno-associated virus vectors","volume":"21","author":"Daya","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jhepr.2021.100300_bib67","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/21678707.2015.1039511","article-title":"Recombinant adeno-associated virus vectors in the treatment of rare diseases","author":"Hastie","year":"2015","journal-title":"Expert Opin Orphan Drugs Inform Healthc"},{"key":"10.1016\/j.jhepr.2021.100300_bib68","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-9139-6_20","article-title":"AAV-mediated gene delivery to the liver: overview of current technologies and methods","volume":"1950","author":"Palaschak","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jhepr.2021.100300_bib69","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/hae.13816","article-title":"Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia","volume":"25","author":"Peyvandi","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jhepr.2021.100300_bib70","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/mt.2016.61","article-title":"Superior in\u00a0vivo transduction of human hepatocytes using engineered AAV3 capsid","volume":"24","author":"Vercauteren","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib71","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","article-title":"Capsid modifications for targeting and improving the efficacy of AAV vectors","volume":"12","author":"B\u00fcning","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jhepr.2021.100300_bib72","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1039\/C9SC04189C","article-title":"Chemical modification of the adeno-associated virus capsid to improve gene delivery","volume":"11","author":"M\u00e9vel","year":"2020","journal-title":"Chem Sci"},{"key":"10.1016\/j.jhepr.2021.100300_bib73","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/hum.2019.264","article-title":"High-throughput in vitro, ex vivo, and in vivo screen of adeno-associated virus vectors based on physical and functional transduction","volume":"31","author":"Westhaus","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib74","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/mt.2008.167","article-title":"DNA shuffling of adeno-associated virus yields functionally diverse viral progeny","volume":"16","author":"Koerber","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib75","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature12875","article-title":"Selection and evaluation of clinically relevant AAV variants in a xenograft liver model","volume":"506","author":"Lisowski","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2021.100300_bib76","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ymthe.2017.09.021","article-title":"Bioengineered AAV capsids with combined high human liver transduction in\u00a0vivo and unique humoral seroreactivity","volume":"26","author":"Paulk","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib77","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/mt.2015.174","article-title":"Efficient and targeted transduction of nonhuman primate liver with systemically delivered optimized AAV3B vectors","volume":"23","author":"Li","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib78","doi-asserted-by":"crossref","first-page":"16029","DOI":"10.1038\/mtm.2016.29","article-title":"Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors","volume":"3","author":"Ling","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jhepr.2021.100300_bib79","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.omtm.2020.09.019","article-title":"Engineering and in\u00a0vitro selection of a novel AAV3B variant with high hepatocyte tropism and reduced seroreactivity","volume":"19","author":"Biswas","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jhepr.2021.100300_bib80","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-Factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib81","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib82","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"S1","key":"10.1016\/j.jhepr.2021.100300_bib83","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/blood-2018-99-115495","article-title":"A\u00a0phase 1\/2 trial of investigational Spk-8011 in hemophilia a demonstrates durable expression and prevention of bleeds","volume":"132","author":"High","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jhepr.2021.100300_bib84","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high specific- activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib85","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib86","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jhep.2016.05.012","article-title":"Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria","volume":"65","author":"D'Avola","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100300_bib87","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1128\/JVI.75.15.6969-6976.2001","article-title":"Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in\u00a0vivo","volume":"75","author":"Nakai","year":"2001","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhepr.2021.100300_bib88","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.ymthe.2017.09.020","article-title":"Survival advantage of both human hepatocyte xenografts and genome-edited hepatocytes for treatment of \u03b1-1 antitrypsin deficiency","volume":"25","author":"Borel","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib89","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature13864","article-title":"Promoterless gene targeting without nucleases ameliorates haemophilia B in mice","volume":"517","author":"Barzel","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2021.100300_bib90","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.15252\/emmm.201707601","article-title":"Promoterless gene targeting without nucleases rescues lethality of a Crigler-Najjar syndrome mouse model","volume":"9","author":"Porro","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib91","article-title":"Promoterless, nuclease-free genome editing confers a growth advantage for corrected hepatocytes in mice with methylmalonic acidemia","author":"Chandler","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100300_bib92","article-title":"Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases","volume":"5","author":"De Caneva","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhepr.2021.100300_bib93","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1089\/hum.2020.049","article-title":"Adeno-associated virus and hematopoietic stem cells: the potential of adeno-associated virus hematopoietic stem cells in genetic medicines","volume":"31","author":"Chatterjee","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib94","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.16106.1","article-title":"Making gene editing a therapeutic reality","volume":"7","author":"Conboy","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.jhepr.2021.100300_bib95","doi-asserted-by":"crossref","first-page":"100065","DOI":"10.1016\/j.jhepr.2019.100065","article-title":"Efficient in\u00a0vivo editing of OTC-deficient patient-derived primary human hepatocytes","volume":"2","author":"Ginn","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2021.100300_bib96","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In\u00a0vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2021.100300_bib97","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/hep.30773","article-title":"Prevention of cholestatic liver disease and reduced tumorigenicity in a murine model of PFIC type 3 using hybrid AAV-piggyBac gene therapy","volume":"70","author":"Siew","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100300_bib98","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/hep.27842","article-title":"Modeling correction of severe urea cycle defects in the growing murine liver using a hybrid recombinant adeno-associated virus\/piggyback transposase gene delivery system","volume":"62","author":"Cunningham","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100300_bib99","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.3390\/cells9102227","article-title":"Use of a hybrid adeno-associated viral vector transposon system to deliver the insulin gene to diabetic NOD mice","volume":"9","author":"La","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jhepr.2021.100300_bib100","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1002\/1873-3468.13691","article-title":"State-of-the-art human adenovirus vectorology for therapeutic approaches","volume":"593","author":"Gao","year":"2019","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jhepr.2021.100300_bib101","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.3390\/ijms21103643","article-title":"High-capacity adenoviral vectors: expanding the scope of gene therapy","volume":"21","author":"Ricobaraza","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhepr.2021.100300_bib102","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/gt.2015.107","article-title":"Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1","volume":"23","author":"Castello","year":"2016","journal-title":"Gene Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib103","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41434-019-0061-z","article-title":"Helper-dependent adenovirus-mediated gene transfer of a secreted LDL receptor\/transferrin chimeric protein reduces aortic atherosclerosis in LDL receptor-deficient mice","volume":"26","author":"Leggiero","year":"2019","journal-title":"Gene Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib104","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ymthe.2020.01.006","article-title":"Adenovirus-antibody complexes contributed to lethal systemic inflammation in a gene therapy trial","volume":"28","author":"Somanathan","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib105","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib106","doi-asserted-by":"crossref","first-page":"565","DOI":"10.5483\/BMBRep.2020.53.11.185","article-title":"Helper virus-free gutless adenovirus (HF-GLAd): a new platform for gene therapy","volume":"53","author":"Liu","year":"2020","journal-title":"BMB Rep"},{"key":"10.1016\/j.jhepr.2021.100300_bib107","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.actbio.2019.06.059","article-title":"Exploring the functions of polymers in adenovirus-mediated gene delivery: evading immune response and redirecting tropism","volume":"97","author":"Sun","year":"2019","journal-title":"Acta Biomate"},{"key":"10.1016\/j.jhepr.2021.100300_bib108","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.omtm.2020.01.014","article-title":"A\u00a0single \"All-in-One\" helper-dependent adenovirus to deliver donor DNA and CRISPR\/Cas9 for efficient homology-directed repair","volume":"17","author":"Palmer","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jhepr.2021.100300_bib109","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.omtm.2019.10.003","article-title":"Bi-allelic homology-directed repair with helper dependent adenoviruses","volume":"15","author":"Palmer","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jhepr.2021.100300_bib110","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/mt.2010.169","article-title":"Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B","volume":"18","author":"Hausl","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib111","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.2174\/138161211797247587","article-title":"Retroviral vector-mediated gene therapy for metabolic diseases: an update","volume":"17","author":"Ferry","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jhepr.2021.100300_bib112","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1089\/hum.2019.190","article-title":"Gene-based approaches to inherited neurometabolic diseases","volume":"30","author":"Poletti","year":"2019","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib113","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1073\/pnas.89.1.89","article-title":"Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes","volume":"89","author":"Kay","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2021.100300_bib114","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/hum.1992.3.5-501","article-title":"Transplantation of genetically modified autologous hepatocytes into nonhuman primates: feasibility and short-term toxicity","volume":"3","author":"Grossman","year":"1992","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib115","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/ng0396-266","article-title":"Hepatocytes corrected by gene therapy are selected in\u00a0vivo in a murine model of hereditary tyrosinaemia type I","volume":"12","author":"Overturf","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2021.100300_bib116","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00000658-199602000-00002","article-title":"Safety and feasibility of liver-directed ex\u00a0vivo gene therapy for homozygous familial hypercholesterolemia","volume":"223","author":"Raper","year":"1996","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhepr.2021.100300_bib117","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/096368979800700611","article-title":"Long-term amelioration of bilirubin glucuronidation defect in Gunn rats by transplanting genetically modified immortalized autologous hepatocytes","volume":"7","author":"Tada","year":"1998","journal-title":"Cell Transpl"},{"key":"10.1016\/j.jhepr.2021.100300_bib118","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/104303401750061230","article-title":"Engraftment of autologous retrovirally transduced hepatocytes after intraportal transplantation into nonhuman primates: implication for ex gene therapy","volume":"12","author":"Andreoletti","year":"2001","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib119","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/nm1195-1148","article-title":"A\u00a0pilot study of ex\u00a0vivo gene therapy for homozygous familial hypercholesterolaemia","volume":"1","author":"Grossman","year":"1995","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jhepr.2021.100300_bib120","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1053\/jhep.2003.50183","article-title":"Repopulation of rat liver by fetal hepatoblasts and adult hepatocytes transduced ex\u00a0vivo with lentiviral vectors","volume":"37","author":"Oertel","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100300_bib121","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1089\/ten.tea.2015.0427","article-title":"Primary human hepatocytes repopulate livers of mice after in vitro culturing and lentiviral-mediated gene transfer","volume":"22","author":"Bierwolf","year":"2016","journal-title":"Tissue Eng Part A"},{"key":"10.1016\/j.jhepr.2021.100300_bib122","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/0963689718814188","article-title":"Autologous gene and cell therapy provides safe and long-term curative therapy in A large pig model of hereditary tyrosinemia type 1","volume":"28","author":"Hickey","year":"2019","journal-title":"Cell Transpl"},{"key":"10.1016\/j.jhepr.2021.100300_bib123","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.8211118","article-title":"In\u00a0vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs","volume":"262","author":"Kay","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2021.100300_bib124","doi-asserted-by":"crossref","first-page":"8377","DOI":"10.1073\/pnas.88.19.8377","article-title":"Retroviral-mediated gene transfer into hepatocytes in\u00a0vivo","volume":"88","author":"Ferry","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2021.100300_bib125","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbrc.2005.01.049","article-title":"Follistatin allows efficient retroviral-mediated gene transfer into rat liver","volume":"328","author":"Borgnon","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhepr.2021.100300_bib126","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0168-8278(00)80358-X","article-title":"Enhancement of retrovirus-mediated gene transfer to rat liver in\u00a0vivo by infusion of hepatocyte growth factor and triiodothyronine","volume":"33","author":"Minami","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100300_bib127","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s002770050504","article-title":"An efficient retrovirus-mediated transduction of human blood coagulation factor VIII cDNA in regenerating rat liver","volume":"78","author":"Oh","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jhepr.2021.100300_bib128","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0016-5085(00)70266-6","article-title":"Synergistic growth factors enhance rat liver proliferation and enable retroviral gene transfer via a peripheral vein","volume":"118","author":"Forbes","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100300_bib129","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jhep.2004.04.015","article-title":"Long term transgene expression by hepatocytes transduced with retroviral vectors requires induction of immune tolerance to the transgene","volume":"41","author":"Puppi","year":"2004","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100300_bib130","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1006\/mthe.2002.0561","article-title":"Cytotoxic immune response blunts long-term transgene expression after efficient retroviral-mediated hepatic gene transfer in rat","volume":"5","author":"Aubert","year":"2002","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib131","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/lt.500040111","article-title":"Long-term reduction of serum bilirubin levels in Gunn rats by retroviral gene transfer in\u00a0vivo","volume":"4","author":"Tada","year":"1998","journal-title":"Liver Transpl Surg"},{"key":"10.1016\/j.jhepr.2021.100300_bib132","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1089\/hum.2019.113","article-title":"Gene therapy for methylmalonic acidemia: past, present, and future","volume":"30","author":"Chandler","year":"2019","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib133","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1093\/hmg\/ddu746","article-title":"Hepatic lentiviral gene transfer prevents the long-term onset of hepatic tumours of glycogen storage disease type 1a in mice","volume":"24","author":"Clar","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jhepr.2021.100300_bib134","doi-asserted-by":"crossref","first-page":"277ra28","DOI":"10.1126\/scitranslmed.aaa1405","article-title":"Liver-directed lentiviral gene therapy in a dog model of hemophilia B","volume":"7","author":"Cantore","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib135","article-title":"Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates","volume":"22","author":"Milani","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib136","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2003-01-0167","article-title":"Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion","volume":"102","author":"Powell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jhepr.2021.100300_bib137","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143780","article-title":"Overcoming innate immune barriers that impede AAV gene therapy vectors","volume":"131","author":"Muhuri","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhepr.2021.100300_bib138","doi-asserted-by":"crossref","first-page":"608249","DOI":"10.3389\/fmed.2020.608249","article-title":"Development and use of gene therapy orphan drugs-ethical needs for a broader cooperation between the pharmaceutical industry and society","volume":"7","author":"Kerpel-Fronius","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib139","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","author":"Chand","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100300_bib140","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib141","first-page":"2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results - potential impact of CpG sequences on gene expression","author":"Konkle","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jhepr.2021.100300_bib142","first-page":"258","article-title":"Of rAAV and men: from genetic neuromuscular disorder efficacy and toxicity preclinical studies to clinical trials and back","volume":"10","author":"Buscara","year":"2020","journal-title":"J\u00a0Pers Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib143","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/bloodadvances.2019000380","article-title":"Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates","volume":"3","author":"Salas","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jhepr.2021.100300_bib144","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in\u00a0vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2021.100300_bib145","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/gutjnl-2019-318281","article-title":"Adeno-associated virus in the liver: natural history and consequences in tumour development","volume":"69","author":"La Bella","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100300_bib146","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2021.100300_bib147","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol Ther"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921000768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921000768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:25:54Z","timestamp":1762899954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555921000768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":147,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S2589555921000768"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100300","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel vectors and approaches for gene therapy in liver diseases","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100300"}}